ArrayCGH Prenatal

ArrayCGH Prenatal is a diagnostic test based on comparative genomic hybridization, designed to detect gains or losses of genetic material that affect fetal development, providing essential information for diagnosis and clinical counseling.

In pregnancies with abnormalities detected by ultrasound, it has been observed that the use of array CGH can increase the genetic diagnosis rate by 5-10% compared to conventional karyotyping , providing key information for the prognosis and clinical management of the newborn.

The test includes 60,000 probes distributed throughout the entire human genome, allowing the detection of alterations from 2 Mb throughout the genome, which implies a 10-fold increase in the resolution of conventional karyotyping. Veritas ArrayCGH Prenatal includes 124 genetic syndromes associated with intellectual disability and congenital disorders, avoiding the detection of regions of susceptibility or incomplete penetrance, which generate uncertainty. In the critical regions related to these syndromes, the resolution is 50 times greater than that of a conventional karyotype, allowing alterations of around 250 Kb to be detected.

Who is it recommended for?

• High-risk pregnancies or pregnancies with ultrasound findings, especially when multiple structural malformations are observed, intrauterine growth retardation without apparent cause, or patterns of abnormalities suggesting a genetic syndrome.
• Confirmation of results in altered karyotypes.
• Analysis of miscarriage remains in cases of recurrent pregnancy loss.